Compare Stocks

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$6.79 -1.5%	$9.54	$2.09 ▼ $14.84	$481.34M	0.05	5.49 million shs	2.31 million shs
AMT American Tower	$171.37 +0.2%	$192.37	$154.58 ▼ $219.10	$79.92B	0.67	2.41 million shs	1.79 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-2.13%	-17.98%	-21.17%	-25.51%	+15.41%
AMT American Tower	-0.59%	-4.28%	-13.03%	-16.12%	-17.84%

Biden replacement revealed? (Ad)

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	1.1183 of 5 stars	3.3	2.0	0.0	0.0	1.7	1.7	0.0
AMT American Tower	4.926 of 5 stars	4.4	3.0	2.5	3.1	2.8	2.5	1.9

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.67	Moderate Buy	$15.00	120.91% Upside
AMT American Tower	2.82	Moderate Buy	$217.36	26.84% Upside

Current Analyst Ratings

Latest MX1, ADR, AMT, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2024	AMT American Tower	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$183.00 ➝ $196.00
4/8/2024	AMT American Tower	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$205.00
4/1/2024	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
3/28/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
3/5/2024	AMT American Tower	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$224.00 ➝ $234.00
2/28/2024	AMT American Tower	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$235.00 ➝ $228.00
2/28/2024	AMT American Tower	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$236.00 ➝ $230.00
2/13/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
1/24/2024	ALT Altimmune	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$13.00
1/24/2024	AMT American Tower	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$229.00 ➝ $224.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$430K	1,119.40	N/A	N/A	$2.75 per share	2.47
AMT American Tower	$11.14B	7.17	$9.87 per share	17.36	$23.30 per share	7.35

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.45M	-$1.65	N/A	N/A	N/A	-20,780.75%	-44.77%	-40.72%	5/9/2024 (Estimated)
AMT American Tower	$1.48B	$3.18	53.89	16.61	1.36	13.31%	12.80%	2.24%	4/30/2024 (Confirmed)

Latest MX1, ADR, AMT, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/30/2024	N/A	AMT American Tower	$2.45	N/A	-$2.45	N/A	N/A	N/A
2/27/2024	12/31/2023	AMT American Tower	$2.10	$0.94	-$1.16	$0.18	$2.74 billion	$2.79 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
AMT American Tower	$6.48	3.78%	+12.50%	203.77%	N/A

Latest MX1, ADR, AMT, and ALT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/14/2024	AMT American Tower	quarterly	$1.62	3.3%	4/11/2024	4/12/2024	4/26/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	17.26	17.26
AMT American Tower	3.29	0.69	0.69

Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
AMT American Tower	92.69%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
AMT American Tower	0.24%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	59	70.89 million	67.99 million	Optionable
AMT American Tower	5,643	466.35 million	465.23 million	Optionable

MX1, ADR, AMT, and ALT Headlines

Source	Headline
	American Tower Co. (NYSE:AMT) Stake Decreased by Ninety One UK Ltd marketbeat.com - April 19 at 8:54 AM
	American Tower Co. (NYSE:AMT) Receives Consensus Rating of "Moderate Buy" from Analysts americanbankingnews.com - April 19 at 2:34 AM
	American Tower (AMT) Dips More Than Broader Market: What You Should Know finance.yahoo.com - April 18 at 11:30 PM
	Cambridge Trust Co. Has $18.76 Million Stake in American Tower Co. (NYSE:AMT) marketbeat.com - April 18 at 2:50 PM
	Daiwa Securities Group Inc. Trims Stake in American Tower Co. (NYSE:AMT) marketbeat.com - April 17 at 6:35 PM
	Invest Like a Hawk: 7 Stocks to Own If the Fed Stays Tough investorplace.com - April 17 at 12:55 PM
	SVB Wealth LLC Lowers Stock Holdings in American Tower Co. (NYSE:AMT) marketbeat.com - April 16 at 11:28 AM
	Morgan Stanley Sticks to Its Hold Rating for American Tower (AMT) markets.businessinsider.com - April 16 at 9:13 AM
	American Tower (NYSE:AMT) Given New $196.00 Price Target at Morgan Stanley americanbankingnews.com - April 16 at 4:50 AM
	American Tower Co. (NYSE:AMT) Shares Purchased by First American Trust FSB marketbeat.com - April 15 at 9:50 PM
	American Tower (NYSE:AMT) PT Raised to $196.00 marketbeat.com - April 15 at 12:16 PM
	Louisiana State Employees Retirement System Makes New Investment in American Tower Co. (NYSE:AMT) marketbeat.com - April 14 at 10:55 AM
	American Tower (NYSE:AMT): An Attractive REIT Stock Backed by Analysts msn.com - April 12 at 2:21 PM
	Impax Asset Management Group plc Buys Shares of 18,093 American Tower Co. (NYSE:AMT) marketbeat.com - April 11 at 8:00 AM
	American Tower Sees Unusually High Options Volume (NYSE:AMT) americanbankingnews.com - April 11 at 2:34 AM
	Investors Buy Large Volume of Call Options on American Tower (NYSE:AMT) marketbeat.com - April 10 at 8:16 PM
	Real-Estate Stocks Slump After Inflation Print finance.yahoo.com - April 10 at 3:45 PM
	American Tower Co. (NYSE:AMT) Shares Sold by Value Partners Investments Inc. marketbeat.com - April 10 at 12:47 PM
	Soltis Investment Advisors LLC Acquires 7,414 Shares of American Tower Co. (NYSE:AMT) marketbeat.com - April 9 at 7:37 PM
	Tech-Driven Education: American Tower & ProFuturo Collabo za.investing.com - April 9 at 1:30 PM
	Here's Why You Should Keep American Tower (AMT) in Your Kitty zacks.com - April 9 at 11:11 AM
	CoreSite Helps Customers Accelerate Artificial Intelligence Adoption as NVIDIA DGX-Ready Data Center Partner businesswire.com - April 9 at 11:00 AM
	Mizuho Initiates Coverage on American Tower (NYSE:AMT) americanbankingnews.com - April 9 at 3:46 AM
	XLRE: Quality Beats Quantity Once Again seekingalpha.com - April 9 at 1:42 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
April 9, 2024 6:07 AM
View Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?

All Headlines

Company Descriptions

Altimmune

NASDAQ:ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

American Tower

NYSE:AMT

American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial